Stratos Wealth Advisors LLC Acquires Shares of 5,565 CRISPR Therapeutics AG $CRSP

Stratos Wealth Advisors LLC acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 5,565 shares of the company’s stock, valued at approximately $271,000.

Several other large investors have also bought and sold shares of the company. IFP Advisors Inc boosted its position in CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after acquiring an additional 181 shares in the last quarter. SFE Investment Counsel lifted its holdings in shares of CRISPR Therapeutics by 5.8% during the first quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock valued at $221,000 after purchasing an additional 355 shares during the last quarter. Axxcess Wealth Management LLC lifted its holdings in shares of CRISPR Therapeutics by 4.0% during the first quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company’s stock valued at $351,000 after purchasing an additional 393 shares during the last quarter. GF Fund Management CO. LTD. lifted its holdings in shares of CRISPR Therapeutics by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after purchasing an additional 394 shares during the last quarter. Finally, Ipswich Investment Management Co. Inc. lifted its holdings in shares of CRISPR Therapeutics by 1.7% during the second quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company’s stock valued at $1,214,000 after purchasing an additional 425 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on CRSP shares. Chardan Capital reiterated a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Royal Bank Of Canada lifted their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a report on Tuesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Barclays lifted their target price on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $72.59.

CRISPR Therapeutics Stock Up 7.0%

Shares of NASDAQ CRSP opened at $73.97 on Tuesday. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48. The firm has a market cap of $6.73 billion, a P/E ratio of -13.62 and a beta of 1.84. The company has a 50 day moving average of $60.81 and a 200 day moving average of $50.52.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. During the same period in the previous year, the business earned ($1.49) EPS. The firm’s revenue for the quarter was up 72.5% on a year-over-year basis. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the completion of the sale, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,213 shares of company stock valued at $3,810,458. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.